1. Home
  2. BNKK vs CVKD Comparison

BNKK vs CVKD Comparison

Compare BNKK & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bonk Inc.

BNKK

Bonk Inc.

N/A

Current Price

$2.59

Market Cap

18.9M

ML Signal

N/A

Logo Cadrenal Therapeutics Inc.

CVKD

Cadrenal Therapeutics Inc.

HOLD

Current Price

$6.81

Market Cap

20.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BNKK
CVKD
Founded
2018
2022
Country
United States
United States
Employees
N/A
N/A
Industry
Package Goods/Cosmetics
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.9M
20.7M
IPO Year
2020
2023

Fundamental Metrics

Financial Performance
Metric
BNKK
CVKD
Price
$2.59
$6.81
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$32.00
AVG Volume (30 Days)
325.8K
85.1K
Earning Date
11-19-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,293,124.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
251.44
N/A
52 Week Low
$2.33
$6.42
52 Week High
$46.90
$22.90

Technical Indicators

Market Signals
Indicator
BNKK
CVKD
Relative Strength Index (RSI) N/A 35.29
Support Level N/A $6.42
Resistance Level N/A $7.62
Average True Range (ATR) 0.00 0.88
MACD 0.00 -0.13
Stochastic Oscillator 0.00 7.65

Price Performance

Historical Comparison
BNKK
CVKD

About BNKK Bonk Inc.

Bonk Inc is a publicly traded company focused on building a digital asset treasury centered around the BONK ecosystem on the Solana blockchain. It generates revenue through a recurring interest in the memecoin launchpad letsBONK.fun and actively manages its treasury of BONK tokens.

About CVKD Cadrenal Therapeutics Inc.

Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.

Share on Social Networks: